An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto): CADTH Reimbursement Review: Therapeutic area: Metastatic castration-resistant prostate cancer [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May.
Top results in this bookTable of Contents
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R, Varley-Campbell J, Tikhonova I, et al.
Southampton (UK): NIHR Journals Library; 2018 Sep. (Health Technology Assessment, No. 22.49.)
Lutetium (177Lu) oxodotreotide (Lutathera): CADTH Reimbursement Review: Therapeutic area: Gastroenteropancreatic neuroendocrine tumours [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jan.
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2025 Jan-.
Lutetium (177Lu) Oxodotreotide (Lutathera): CADTH Reimbursement Recommendation: Indication: For the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor (SSR)–positive pancreatic neuroendocrine tumours (pNETs) in adults whose disease has progressed after treatment with a somatostatin analogue (SSA), unless there is a contraindication or intolerance [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct.
Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto): CADTH Reimbursement Recommendation: Indication: Treatment of adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have received at least one androgen receptor pathway inhibitor and taxane-based chemotherapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Molecular Imaging and Therapy [Internet].
Hall LT, editor.
Brisbane (AU): Exon Publications; 2023 Nov 8.
Advancing Nuclear Medicine Through Innovation.
National Research Council (US) and Institute of Medicine (US) Committee on State of the Science of Nuclear Medicine.
Washington (DC): National Academies Press (US); 2007.
Prostate-Specific Membrane Antigen PET-CT Imaging for the Staging of Prostate Cancer in Canada: CMII Report [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.
Drugs and Lactation Database (LactMed®) [Internet].
Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
Molecular Imaging and Contrast Agent Database (MICAD) [Internet].
Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
Trace Metals and Infectious Diseases [Internet].
Nriagu JO, Skaar EP, editors.
Cambridge (MA): MIT Press; 2015.
Olaparib (Lynparza): CADTH Reimbursement Review: Therapeutic area: Metastatic castration-resistant prostate cancer (mCRPC) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Apr.
Holland-Frei Cancer Medicine. 6th edition.
Kufe DW, Pollock RE, Weichselbaum RR, et al., editors.
Hamilton (ON): BC Decker; 2003.
Prostate Cancer [Internet].
Bott SRJ, Ng KL, editors.
Brisbane (AU): Exon Publications; 2021 May 27.
Olaparib (Lynparza): CADTH Reimbursement Recommendation: Indication: In combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before olaparib treatment is initiated [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb.
Regulatory Processes for Rare Disease Drugs in the United States and European Union: Flexibilities and Collaborative Opportunities.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union; Shore CK, Worku TL, Smith CW, et al., editors.
Washington (DC): National Academies Press (US); 2024 Oct 30.
Radiation.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.
Lyon (FR): International Agency for Research on Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 100D.)
Endotext [Internet].
Feingold KR, Anawalt B, Blackman MR, et al., editors.
South Dartmouth (MA): MDText.com, Inc.; 2000-.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on